PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
01-May-2025 First patient enrolled in Phase 1 clinical trial of Akiram’s cancer drug candidate AKIR001 Akiram Therapeutics
01-May-2025 PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference PureTech
01-May-2025 argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) argenx
30-Apr-2025 Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025 Domain Therapeutics
24-Apr-2025 MAGIC-I study to revolutionise childhood cancer care in Ireland University College Dublin
24-Apr-2025 EMAS Pharma Rebrands as Evestia Clinical Evestia Clinical
15-Apr-2025 CluePoints’ Technology Named as Finalist in 2025 Citeline Awards CluePoints
15-Apr-2025 Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA HighTide Therapeutics, Inc.
15-Apr-2025 1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research 1ST Biotherapeutics
14-Apr-2025 New GDP Training with Certificate Pharma Lessons
11-Apr-2025 Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Theriva Biologics
10-Apr-2025 Phastar Secures Finalist Spot at 2025 Citeline Awards Phastar
09-Apr-2025 Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System Microbot Medical
09-Apr-2025 Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development Ebenbuild
08-Apr-2025 Richmond Pharmacology completes first cohort dosing in Hemab Therapeutics Phase1/2 Clinical Trial Investigating HMB-002 for Von Willebrand disease Richmond Pharmacology
03-Apr-2025 Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions Cambridge Cognition
03-Apr-2025 Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis Roche
02-Apr-2025 AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease AC Immune
01-Apr-2025 CluePoints Appoints Usama Dar as Chief Product and Technology Officer CluePoints
31-Mar-2025 IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer AstraZeneca